Aurinia Pharmaceuticals Inc. posts strong 2025 revenue growth and outlines strategic progress across its commercial and clinical pipeline.
Aurinia Pharmaceuticals Inc. has reported strong financial and operational performance for the fourth quarter and full year ended December 31, 2025, highlighting continued commercial momentum for its lead product, LUPKYNIS, and providing a confident outlook for 2026.
Strong Revenue Growth Driven by LUPKYNIS
For the three months ended December 31, 2025, Aurinia generated total revenue of $77.1 million, representing a 29% increase compared to $59.9 million in the same period of 2024. For the full year 2025, total revenue reached $283.1 million, up 20% from $235.1 million in 2024. The consistent year-over-year growth underscores the company’s expanding commercial footprint and sustained demand for its flagship therapy.
The majority of Aurinia’s revenue continues to be driven by net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Fourth-quarter 2025 net product sales totaled $74.2 million, up 29% from $57.6 million in the fourth quarter of 2024. For the full year, LUPKYNIS generated $271.3 million in net product sales, marking a 25% increase compared to $216.2 million in 2024.
The continued growth of LUPKYNIS reflects increasing physician adoption, broader patient access, and sustained efforts to raise awareness of lupus nephritis, a serious autoimmune disease affecting the kidneys. As the only FDA-approved oral therapy specifically indicated for this condition, LUPKYNIS remains central to Aurinia’s commercial strategy.
Collaboration and Royalty Revenue Trends
In addition to product sales, Aurinia reported revenue from licenses, collaborations, royalties, and manufacturing services. For the fourth quarter of 2025, this segment generated $2.9 million, a 26% increase compared to $2.3 million in the same period of 2024.
However, for the full year 2025, license, collaboration, and royalty revenue totaled $11.7 million, representing a 38% decline from $18.9 million in 2024. The year-over-year decrease is primarily attributable to a $10.0 million milestone payment recognized in 2024 related to regulatory approval of LUPKYNIS in Japan. That milestone, tied to Aurinia’s collaboration with Otsuka Pharmaceutical Co., Ltd., did not recur in 2025, resulting in a lower annual comparison.
Despite the decline in annual collaboration revenue, the underlying performance of the LUPKYNIS franchise remains robust and continues to offset variability in milestone-driven income.
Significant Expansion in Net Income
Aurinia reported substantial improvements in profitability in 2025. For the fourth quarter, net income was $210.8 million, a dramatic increase compared to $1.4 million in the fourth quarter of 2024. For the full year, net income reached $287.2 million, compared to $5.8 million in 2024.
These increases represent year-over-year growth of 14,957% for the quarter and 4,852% for the full year. A significant driver of this surge was the recognition of an income tax benefit. During 2025, Aurinia recorded an income tax benefit of $175.1 million in the fourth quarter and $173.0 million for the full year, primarily related to the release of its valuation allowance on deferred tax assets. The company now expects to realize these deferred tax assets due to its sustained profitability trajectory.
Excluding income taxes, net income before income taxes was also substantially higher. For the fourth quarter of 2025, net income before income taxes totaled $35.7 million, compared to $1.2 million in the prior-year quarter—an increase of 2,875%. For the full year, pre-tax income reached $114.2 million, up 1,443% from $7.4 million in 2024. These figures highlight meaningful operational leverage and improving core profitability beyond one-time accounting adjustments.
Earnings Per Share Reflect Profitability Gains
Diluted earnings per share (EPS) followed a similar upward trajectory. For the fourth quarter of 2025, diluted EPS was $1.53, compared to $0.01 in the same period of 2024. For the full year, diluted EPS was $2.07, up from $0.04 in 2024.
The significant improvement in EPS reflects higher net income combined with disciplined capital management, including share repurchases conducted during the year.
Operating Cash Flow Strengthens Financial Position
Aurinia’s operating performance translated into improved cash generation. For the fourth quarter of 2025, cash flows from operating activities were $45.7 million, up 52% from $30.1 million in the fourth quarter of 2024. For the full year, operating cash flow reached $135.7 million, representing a 206% increase compared to $44.4 million in 2024.
The substantial rise in operating cash flow signals growing self-sustainability and reduced reliance on external financing, positioning the company for continued strategic investments.
Solid Cash Position and Share Repurchases
As of December 31, 2025, Aurinia reported $398.0 million in cash, cash equivalents, restricted cash, and investments, compared to $358.5 million at the end of 2024. This strengthened liquidity position provides financial flexibility to support commercial expansion, clinical development programs, and shareholder returns.
During 2025, the company repurchased 12.2 million common shares for approximately $98.2 million. The share buyback program demonstrates management’s confidence in the company’s long-term value and commitment to enhancing shareholder returns.
2026 Financial Guidance Points to Continued Growth
Looking ahead, Aurinia provided revenue guidance for 2026 that indicates continued momentum. The company expects total revenue in the range of $315 million to $325 million, representing growth of approximately 11% to 15% compared to 2025.
Net product sales of LUPKYNIS are projected to reach $305 million to $315 million, reflecting anticipated growth of 12% to 16% year over year. The guidance suggests ongoing adoption among lupus nephritis patients and continued commercial execution.
Pipeline Progress: Advancing Aritinercept
Beyond its commercial performance, Aurinia is also investing in pipeline expansion. President and Chief Executive Officer Peter Greenleaf expressed confidence in the company’s outlook, emphasizing both commercial growth and pipeline advancement.
A key area of focus is aritinercept, a dual BAFF/APRIL inhibitor with potential applications across multiple autoimmune diseases. The company has initiated a clinical study of aritinercept in one autoimmune indication and plans to launch an additional clinical study in the first half of 2026.
This pipeline strategy aims to diversify Aurinia’s portfolio beyond lupus nephritis and leverage its expertise in autoimmune disease treatment. If successful, aritinercept could represent a significant long-term growth driver.
Investor Engagement
To discuss its financial results and business outlook, Aurinia is hosting a webcast and conference call on February 26 at 8:30 a.m. ET. A replay of the webcast will be made available on the company’s website for investors and stakeholders who are unable to attend the live event.
